COMPOSITION

Each film coated tablet contains trimetazidine (as dihydrochloride) 35 mg.

THERAPEUTIC INDICATIONS

Cardiology:
- continuous care of ischemiac heart-disease: the prevention of stenocardia attack in monotherapy or in combination with other preparations.
Otolaryngology:
- treatment of cochlear-vestibular disorders of ischemiac origin: dizziness, buzzing in the ears, hypocausts.
Ophthalmology:
- chorioretinal disorders with ischemiac elements.

CONTRAINDICATIONS

- Hypersensitivity to components of the preparation;
- Period of lactation.

ADVERSE EFFECTS

The preparation is well tolerated, but sometimes the rise of insignificant by effects is possible.
From the digestion system: sickness, vomiting.
From the coverlet: itch, nettle rash.

DOSAGE AND ADMINISTRATION

It is recommended to take Carmetadin in 1 tablet 2 times/day (in the morning and in the evening) during a meal, without chewing, washing down with little water.
The preparation is taken for a long period. The cure duration is established particularly. The treatment regiment can be revised in 3 months if it is necessary.

PREGNANCY AND LACTATION

Drug application during pregnancy and lactation period is possible only if there are any indications and after careful assessment of benefit/risk ratio.

MANUFACTURED FORM

Film coated tablets with modified release in a blister. 30 tablets in a blister.
2 blisters in carton box with enclosed leaflet.